A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Titel:
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Auteur:
Leijen, Suzanne Soetekouw, Patricia M. M. B. Jeffry Evans, T. R. Nicolson, Marianne Schellens, Jan H. M. Learoyd, Maria Grinsted, Lynda Zazulina, Victoria Pwint, Thinn Middleton, Mark